Literature DB >> 15090290

Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients. Part II: gender differences.

Till Neumann1, T Woiwod, A Neumann, B Ross, C Von Birgelen, L Volbracht, Norbert H Brockmeyer, G Gerken, R Erbel.   

Abstract

OBJECTIVE: Due to the side effects of antiretroviral therapy and long term survival there is an increasing concern of an elevated rate of cardiovascular diseases in HIV-infected patients. The present study analysed the cardiovascular risk profile and the probability of cardiovascular events in HIV-infected patients, due to differences of gender.
METHODS: Cardiovascular risk factors of 309 HIV-infected adults, including 240 males were analysed. Overall 10-years probability for cardiovascular events was evaluated by the Framingham algorithm.
RESULTS: Gender differences were detected in cardiovascular risk factors such as lipid values, blood pressure and the rate of smoking. Tobacco use was much more common in HIV-infected males compared with HIV-infected females (67.5% vs. 49.3%; p<0.001). Although no significant difference was noticed in total cholesterol (5.49 +/- 0.09 vs. 5.53 +/- 0.19 mmol/L, p = 0.84), the HDL-cholesterol concentration was significantly lower (1.09 +/- 0.03 vs. 1.36 +/- 0.06 mmol/L, p < 0.001) and the triglyceride concentration higher (3.01 +/- 0.21 vs. 2.06 +/- 0.26 mmol/L, p = 0.02) in HIV-infected males compared to HIV-infected females. Additionally, systolic blood pressure was higher in HIV-infected males compared with HIV-infected females (123.1 +/- 1.1 vs. 115.4 +/- 2.1 mmHg, p < 0.01). No significant differences were detected in HbA1c concentrations between both groups (5.15 +/- 0.07 vs. 5.31 +/- 0.11, p = 0.26). The overall 10-years probability for cardiovascular events was 8.7% (median) in HIV-infected males and 1.7% in HIV-infected females (p < 0.0001).
CONCLUSIONS: In the present study, we observed gender differences in the cardiovascular risk profile of HIV-infected individuals. The risk of premature atherosclerosis and associated cardiovascular events was significantly higher in HIV-infected males.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15090290

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  7 in total

Review 1.  Plant glutaredoxins: still mysterious reducing systems.

Authors:  N Rouhier; E Gelhaye; J-P Jacquot
Journal:  Cell Mol Life Sci       Date:  2004-06       Impact factor: 9.261

2.  [Coronary artery disease in HIV-infected subjects. Results of 101 coronary angiographies].

Authors:  T Neumann; K A Lülsdorf; P Krings; N Reinsch; R Erbel
Journal:  Herz       Date:  2010-12-23       Impact factor: 1.443

3.  Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.

Authors:  Judith S Currier; Jens D Lundgren; Andrew Carr; Daniel Klein; Caroline A Sabin; Paul E Sax; Jeffrey T Schouten; Marek Smieja
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

4.  Coronary risk assessment in patients with HIV infection: why bother?

Authors:  Stefan Möhlenkamp; Nico Reinsch; Raimund Erbel; Till Neumann
Journal:  Int J Cardiovasc Imaging       Date:  2011-08-26       Impact factor: 2.357

Review 5.  Sex Differences in Tobacco Use Among Persons Living With HIV/AIDS: A Systematic Review and Meta-Analysis.

Authors:  Andrea H Weinberger; Philip H Smith; Allison P Funk; Shayna Rabin; Jonathan Shuter
Journal:  J Acquir Immune Defic Syndr       Date:  2017-04-01       Impact factor: 3.731

6.  Are Physical Fitness and CRP Related to Framingham Risk Score in HIV+ Adults?

Authors:  John E Lewis; Jillian Poles; Eleanor Garretson; Eduard Tiozzo; Sharon Goldberg; Carmen S G Campbell; Herbert G Simões; Judi M Woolger; Janet Konefal
Journal:  Am J Lifestyle Med       Date:  2020-02-11

Review 7.  [HIV, AIDS and the cardiovascular risk].

Authors:  T Neumann
Journal:  Internist (Berl)       Date:  2008-04       Impact factor: 0.743

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.